Eli Lilly and Company Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (36)

Latest Posts

About This Stock More About This Stock
Competition Increases Between Novartis, Lilly & Pfizer For Approval Of New Breast Cancer Drug
Article By: Lorimer Wilson
Monday, March 20, 2017 12:38 PM EDT
Just one week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly & Co. has announced that its long-awaited Phase III readout for its rival drug "abemaciclib" looks good albeit remaining far behind Pfizer in the CDK 4/6 game.
In this article: LLY, NVS, PFE
Read
Week In Review: OrbiMed Plans $450 Million Target For Third Asia Life Science Fund
Article By: ChinaBio® Today
Saturday, March 4, 2017 12:45 PM EDT
OrbiMed filed with the SEC to raise $450 million for its third Asia-focused fund, OrbiMed Asia Partners III. The company says it considers investments in all sectors of life science.
In this article: LLY, KITE, HCM
Read
Eli Lilly’s Fiscal 2016 Earnings: Analyzing The Surprising Results
Article By: SureDividend
Wednesday, February 1, 2017 3:52 PM EDT
Eli Lilly has a solid 2.7% dividend yield. And, now that the company’s growth investments are bearing fruit, it has returned to dividend growth.
In this article: LLY
Read
Pfizer Inc. Shares Fall On Earnings Miss, Eli Lilly And Co. Little Changed On Sales Beat
Article By: ValueWalk
Tuesday, January 31, 2017 9:06 AM EDT
Pfizer reported GAAP earnings of 13 cents per share, swinging from a loss of 3 cents per share in the year-ago quarter. Innovative Health revenues rose 1% to $7.7 billion, while Essential Health sales declined 8% to $5.9 billion.
In this article: LLY, PFE
Read
Drug Stocks Reporting Q4 Earnings On Jan 31: LLY And PFE
Article By: Zacks Investment Research
Monday, January 30, 2017 9:46 AM EDT
Eli Lilly’s bottom-line performance has been mixed so far, with its earnings surpassing expectations in two of the last four quarters, and missing the same in the other two, bringing the average negative surprise to 2.05%.
In this article: PFE, LLY Also: BMY, JNJ, BIIB, CELG
Read

PARTNER HEADLINES

Latest Tweets for $LLY

No tweets yet!